Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–455.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910.
   PubMed Web of Science ®Google Scholar
• Nasr P, Fredrikson M, Ekstedt M, et al. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020;40(5):1069–1078.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, De Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625.e12.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
   PubMed Web of Science ®Google Scholar
• Campbell PT, Newton CC, Patel AV, et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–1844.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, APRICOT Clinical Investigators, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751.
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–1501.
   PubMed Web of Science ®Google Scholar
• Swedish Society of Gastroenterology. Nationell riktlinje – Utredning och handläggning av fettleversjukdom; [Swedish guidelines for NAFLD]. 2020 [cited 2021 May 5]. Available from: https://svenskgastroenterologi.se/wp-content/uploads/2020/02/2020-utredning-och-handlaggning-av-fettleversjukdom.pdf.
   Google Scholar
• Lazarus JV, Palayew A, Carrieri P, et al. European 'NAFLD Preparedness Index' – Is Europe ready to meet the challenge of fatty liver disease? JHEP Rep. 2021;3(2):100234.
   PubMedGoogle Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508.
   PubMedGoogle Scholar
• Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–872.
   PubMed Web of Science ®Google Scholar
• Yip TC, Ma AJ, Wong VW, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther. 2017;46(4):447–456.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group, et al. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366(9491):1059–1062.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56(1):234–240.
   PubMed Web of Science ®Google Scholar
• Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948–963.
   PubMed Web of Science ®Google Scholar
• Käräjämäki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Ann Med. 2018;50(5):371–380.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170.
   PubMed Web of Science ®Google Scholar
• Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100.
   PubMed Web of Science ®Google Scholar
• Andreasson A, Carlsson AC, Önnerhag K, et al. Waist/Hip ratio better predicts development of severe liver disease within 20 years than Body Mass Index: a population-based cohort study . Clin Gastroenterol Hepatol. 2017;15(8):1294–1301.e2.
   PubMed Web of Science ®Google Scholar
• Rådholm K, Chalmers J, Ohkuma T, et al. Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: results from the ADVANCE-ON study. Diabetes Obes Metab. 2018;20(8):1903–1910.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Banh X, Horsfall LU, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144–151.
   PubMed Web of Science ®Google Scholar
• van Asten M, Verhaegh P, Koek G, et al. The increasing burden of NAFLD fibrosis in the general population: time to bridge the gap between hepatologists and primary care. Hepatology. 2017;65(3):1078.
   PubMed Web of Science ®Google Scholar
• Blais P, Husain N, Kramer JR, et al. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015;110(1):10–14. 134
   PubMed Web of Science ®Google Scholar
• Nasr P, Iredahl F, Dahlström N, et al. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol. 2021;21(1):180.
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Muraca E, Perra S, et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8(1):e000904.
   PubMed Web of Science ®Google Scholar
• Tapper EB, Hunink MG, Afdhal NH, et al. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS One. 2016;11(2):e0147237.
   PubMed Web of Science ®Google Scholar
• Tanajewski L, Harris R, Harman DJ, et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7(6):e015659.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, REGENERATE Study Investigators, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M, Ogawa Y, et al. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother. 2020;21(8):953–967.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5.
   PubMed Web of Science ®Google Scholar
• Loomba R, Lim JK, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020;158(6):1822–1830.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology. 2017;65(1):310–335.
   PubMed Web of Science ®Google Scholar